SZL P1-41

Cat. No.: HY-100237

CAS No.: 222716-34-9

Molecular Formula: $C_{24}H_{24}N_2O_3S$

Molecular Weight: 421

Target: E1/E2/E3 Enzyme; Apoptosis

Pathway: Metabolic Enzyme/Protease; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2.5 mg/mL (5.94 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3753 mL	11.8765 mL	23.7530 mL
	5 mM	0.4751 mL	2.3753 mL	4.7506 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: corn oil
   Solubility: 5 mg/mL (11.88 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities[1][2].

IC_{50} & Target

Skp2[1]

In Vitro

SZL P1-41 (5-20μM; 24 hours) induces endogenous p27 protein expression in PC3 cells and also induced expression of p21, another Skp2 substrate[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SZL P1-41 (40-80 mg/kg; i.p.) displays a potent effect on inhibiting prostate and lung tumor growth in Nude mice bearing A549 and PC3 tumor xenografts[1].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Leukemia. 2020 May;34(5):1241-1252.
- Pharmacol Res. 2022 Jan 5;106059.
- Cell Death Dis. 2022 Jul 13;13(7):606.
- Life Sci. 2021 Dec 16;289:120231.
- Commun Biol. 2023 Aug 2;6(1):805.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chan CH et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1;154(3):556-68.

[2]. Chan CH, et al. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014;13(5):679-80.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA